FDA accepts new drug application of Mirati for NSCLC therapy
The US FDA has accepted Mirati Therapeutics’ NDA for its therapy adagrasib to treat KRASG12C-mutated non-small cell lung cancer (NSCLC) patients.
Stay updated with breaking news from Charles Baum. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The US FDA has accepted Mirati Therapeutics’ NDA for its therapy adagrasib to treat KRASG12C-mutated non-small cell lung cancer (NSCLC) patients.
/PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced that the U.S. Food and Drug Administration...
/PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced that the U.S. Food and Drug Administration...
Rutherford County does not stand alone for a price increase in just about every sector of business. State Representative Charlie Baum from Murfreesboro, TN told WGNS NEWS that inflation is causing issues for families and businesses throughout Tennessee.Looking back at 2021 and going into the first two months of 2022, the Consumer Price Index is between 5% to 6.5% nationally. Baum noted that one of the problems is the workforce…Baby boomer’s are those who were born between the end of ...
Odyssey Therapeutics Announces $218 Million Series A Financing to Advance Next Generation Inflammation and Oncology Medicines - read this article along with other careers information, tips and advice on BioSpace